In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Iovance Biotherapeutics Inc (IOVA). The company’s shares closed yesterday at $24.62, close to its 52-week high of $25.50.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.9% and a 42.6% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and Molecular Templates Inc.
Iovance Biotherapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $30.63, a 24.4% upside from current levels. In a report issued on June 28, Piper Jaffray also maintained a Buy rating on the stock with a $30 price target.
See today’s analyst top recommended stocks >>
Based on Iovance Biotherapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $36.95 million. In comparison, last year the company had a GAAP net loss of $30.66 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients’ tumors.
